European Biotech Executives Split on Partnership Future
A survey of 81 leaders highlights a lack of consensus on whether the U.S. or China will anchor future international biotech deals.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you believe now is a good time to invest in high-risk biotech sectors?
Results published October 7, 2026, reveal that European biotech executives remain divided on which global market will drive future innovation partnerships. While 29 respondents pointed to the U.S. and 24 to China, the sector faces significant hurdles in internal growth and competitiveness.
Why it matters
The survey results underscore a profound structural challenge for European firms struggling to secure funding in a competitive global landscape. Industry growth is currently constrained by systemic capital access issues that executives prioritize above all other operational hurdles.
Europe received an average competitiveness score of 2.8 on a five-point scale. Nearly 80% of respondents identified investor risk aversion as the most significant constraint on investment, far exceeding other factors.
The players
BioIndustry Association
A U.K.-based trade association that tracks industry trends and provides advocacy for the life sciences sector.
The details
The survey polled leaders of privately-owned European biotech firms managing preclinical and early clinical assets. Respondents identified access to capital as the most critical industry challenge to resolve, reflecting broader difficulties in scaling operations. These findings align with recent reporting from the BioIndustry Association regarding persistent investor risk aversion in the United Kingdom throughout 2025.
Timeline
2025: BioIndustry Association documented U.K. investor risk aversion.
October 7, 2026: The BIO-Europe survey results were published.
The Tech Race
The findings mirror concerns raised in the 2025 BioIndustry Association investment risk assessment regarding regional funding bottlenecks. Executives are now weighing whether to orient their partnership strategies toward the U.S. or China to bypass these local constraints.
European biotech firms are currently forced to look beyond local markets for the capital needed to transition from preclinical research to clinical trials. This shift may alter which global hubs gain early access to European-developed medical innovations.
The takeaway
The data confirms that capital access remains the central bottleneck for European biotech innovation. Watch for future shifts in investor risk profiles to see if the region can improve its 2.8 competitiveness score.
Further reading
For broader insights into the shifting landscape of international drug development and research, visit the Biotech section.
Source note: This article includes information reported by Pharma.
Live Poll
Do you believe now is a good time to invest in high-risk biotech sectors?
